1 / 76

Cardiac Contractility

Cardiac Contractility. Dapo Odujebe, MD Toxicology Fellow NYC Poison Control Center. Overview. Review & Cases Cardiac Electrophysiology Cardiac Contractility Cardiac Medications Overdose Management Questions?. Case #1.

avel
Download Presentation

Cardiac Contractility

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Cardiac Contractility Dapo Odujebe, MD Toxicology Fellow NYC Poison Control Center

  2. Overview • Review & Cases • Cardiac Electrophysiology • Cardiac Contractility • Cardiac Medications • Overdose Management • Questions?

  3. Case #1 • 45-year old woman PMHx s/f depression presents to the ED after allegedly ingesting all of her anti-HTN medication. • Prescription filled 3 days prior for 30 tablets of diltiazem CD 240 mg. • Patient alert & oriented, mildly diaphoretic and complaining of generalized weakness.

  4. Case #1 • Vital signs: • BP: 76/36, HR: 46, RR: 14, Temp: 98.6 • pOx: 100% RA, AccuChk: 154 • Rest of physical examination is benign. • Patient placed on a cardiac monitor, O2 via nasal cannular and IV access established.

  5. Case #1 • What is the next step in her management?

  6. Case #3 • An 86-year old woman presents with increased confusion and vomiting. • Per family, she’s had increasing weakness, nausea & anorexia over the last 3 days. • Medications: • hydrochlorothiazide • digoxin • furosemide • enteric-coated aspirin • metformin • PMHx: • hypertension • congestive heart failure (CHF) • diabetes mellitus

  7. Case #3 • In the hospital, she is alert, but oriented only to person. • Vital signs are normal, except for a heart rate of 46 beats/minute. She weighs 143 lbs (65 kg). • Her physical examination demonstrates: • bibasilar rales • irregular S1, S2 with a S3 gallop • bilateral LE 2+ pitting edema, up to her shins

  8. Case #3 • ECG: • atrial flutter with variable block • ventricular rate of 40-50 beats/minute with occasional premature ventricular contractions (PVCs). • Laboratory results were within limits except: • potassium - 3.2 mEq/L • creatinine - 1.6 mg/dL • glucose - 235 mg/dL • Initial digoxin serum concentration (SDC): • 3.4 ng/mL (> 6 hours since last dose).

  9. Case #3 • What is the next step in her management?

  10. Cardiac Electrophysiology

  11. Cardiac Electrophysiology • Actions potentials • SA node • Cardiac muscle • (atria, ventricles & Purkinje fibers) • Channels • Ca2+ channel • β-adrenergic receptor • Na+/K+-ATPase

  12. Ca2+ Pacemaker Cell Cycle Phase 0 Phase 3 0 mV -50 mV -70 mV Phase 4 Phase 4

  13. Action potential (SA Node) • Pacemaker of the heart • Unstable resting potential • Exhibits automaticity • AV node & His-Purkinje system are latent pacemakers • Phase 1 & 2 are not present in pacemaker action potentials

  14. Ca2+ Cardiac Muscle Cell Cycle Phase 0 Phase 1 Phase 2 +30 mV 0 mV Phase 3 -70 mV -90 mV Resting Potential Phase 4

  15. 2 K+ 3 Na+ SR (Mitochondria) Ryanodine receptor Na+/K+ ATPase Na+/Ca2+ Antiporter Voltage dependent L-typeCa2+ channel Na+ channel Na+/K+ ATPase K+ channel(s) Ca2+ 3 Na+ β-adrenergic receptor Na+/Ca2+ exchanger Heart muscle Representative Cardiac Cell

  16. Cardiac Contractility

  17. Contractility • Intrinsic ability of cardiac muscle • Also called ‘inotropism’ or ‘inotropy’ • Related to the intracellular [Ca2+] • Inotropic agents • positive: increase contractility • negative: decrease contractility

  18. Factors Increasing Contractility • Increased intracellular [Ca2+] • increased heart rate • cardiac glycosides (e.g. digoxin) • Stimulation of β1-adrenergic receptor • sympathomimetic agents • catecholamines

  19. Contractility - Other Factors • Chronotropy • rate of contraction • also affected by intracellular [Ca2+] • Dromotropy • rate of impulse conduction • noted particularly at AV node

  20. Cardiac Medications & Receptors

  21. Cardiac Medications • Some examples: • Ca2+ channel antagonists/blockers • β-adrenergic antagonists/blockers • Cardiac glycosides (digoxin)

  22. Ca2+ Channel Antagonists

  23. Calcium Channel • Cardiac calcium channels • L-type calcium channel • ryanodine (RyR2) calcium channel • located on the sarcoplasmic reticulum • Critical for: • conduction velocity (AV node) • duration of depolarization • cardiac muscle contraction

  24. Ca2+ Channel Antagonists • Block the L-type calcium channel • negative inotropy in cardiac muscle • decrease available intracellular Ca2+ • negative chronotropy in pacemaker cells • negative dromotropy at the AV node • relaxation of vascular smooth muscle • decreased afterload • decreased systemic blood pressure • increased coronary vascular dilatation

  25. Ca2+ Channel Antagonists • Phentylalkylamines • e.g. verapamil • Benzothiazepines • e.g. diltiazem • Dihydropyridines • e.g. nifedipine • Diarylaminopropylethers • e.g. bepridil • Tetralene Derivatives • e.g. mibefradil

  26. Ca2+ Channel Antagonists • Overdose of CCB • extension of therapeutic effects • Lose their selectivity (mostly) • Negative inotropy (bradycardia) • Negative chronotropy (hypotension) • Vasodilation (hypotension) • Negative dromotropy (AV blocks, brady) • +/- hyperglycemia (depressed insulin) CCB = calcium channel blocker

  27. β-Adrenergic Antagonists

  28. β-Adrenergic Receptors • There are 3 known subtypes of β-adrenergic receptors, namely β1, β2 & β3. • The human heart has predominantly β1 receptors • β2 & β3 exist in ‘small’ quantities

  29. β-Adrenergic Receptors • Stimulation on β1 receptors • increases heart rate • increases contractility • increases conduction velocity • increases automaticity • The effect of adrenergic agents on the heart is mediated through a secondary messenger – cAMP

  30. β-Adrenergic Receptors • Intracellular cAMP concentrations are regulated by 3 components: • adrenergic receptor on the cell surface • a “G-protein” complex • adenyl cyclase – enzyme synth. cAMP • cAMP acts as a secondary messenger • interacts with protein kinase A to increase phosphorylating activity

  31. β-Adrenergic Receptors • Protein kinases transfer a phosphate group from ATP to serine • Thereby, phosphorylating various cellular proteins • phospholamban ( activity) • troponin ( activity) • L-type calcium channels ( activity)

  32. β-Adrenergic Receptors Bers DM. Cardiac excitation-contraction coupling. Nature 2002 415;198 - 205

  33. β-Adrenergic Antagonists • β-Adrenergic antagonists • effects similar to blockade of L-type calcium channel • Clinical effects • decrease contraction (hypotension) • decrease chronotropy (bradycardia) • decrease dromotropy (AV blocks, brady)

  34. β-Adrenergic Antagonists • Extra-cardiac signs of toxicity • neurological disturbances • drowsiness, non-agitated coma • dilated pupils • respiratory depression • Treatment of toxicity is based on: • stimulation of glucagon receptor • restoring intracellular Ca2+ stores

  35. Overdose Management

  36. Overdose Management • Decontamination • Emesis not recommended • Activated charcoal should be considered • Gastric lavage with 36-40 Fr tube • contraindicated in patients w/ bradycardia • consider particularly in patients a/ SR preps • Whole bowel irrigation • particularly a/ SR preps

  37. Overdose Management • Atropine • Adult: 0.5 – 1.0 mg IVP (max 3 mg) • Children: 0.02 mg/kg IVP • given every 2 – 3 minutes • Should be held in patients getting WBI because of anticholinergic effects

  38. Overdose Management • Calcium salts • increases extracellular Ca2+ • calcium gluconate: 1 gm = 4.3 mEq • calcium chloride: 1 gm = 13.4 mEq • Dose • 10 – 20 mL of 10% CaCl2 • 30 – 60 mL of 10% Ca gluconate

  39. Overdose Management • Dose (cont’d) • effect is transient, redose q15 – 20 mins • in adults, can give 50 mL of 10% CaCl2 (5 gm) before having to check a Ca2+ serum concentration • (i.e. 150 mL of 10% Ca gluconate) • CaCl2 is causes sclerosis of peripheral veins and should be given centrally

  40. Overdose Management • Glucagon • activates adenyl cyclase directly via glucagon receptor • adult dose: 2-5 mg slowly IV • can be repeated every 5-10 minutes • total dose should not exceed 10 mg • follow bolus with an infusion of the dose that produced an effect

  41. Overdose Management • Catecholeamines • attempt to competitively antagonize β-adrenergic antagonist at the receptor • no convincing evidence • chance of stimulating other receptors in the required dose to produce competive displacement • if one is used – norepinephrine is probably the best choice

  42. Overdose Management • Insulin & Glucose • growing evidence that used correctly, this increases inotropy and chronotropy • theory: improved Ca2+ entry & improved myocardial carbohydrate use • Dose: 0.5 – 1 Unit/kg/hr regular insulin • give 0.5 gm/kg/hr dextrose (glu > 100) • check glucose every 30 mins initially

  43. Overdose Management • Amrinone • inhibits breakdown of cAMP by phosphodiasterase III • thereby increasing intracellular [] of cAMP • this increases inotropy and chronotropy • BUT, causes vasodilation & hypotension • should be used with a vasopressor

  44. Cardiac glycosides (digoxin)

  45. Therapeutic • Digoxin inhibits Na+/ K+-ATPase • This increases cytosolic Ca2+ which increases inotropy. • Therapeutically: • digoxin increases automaticity • shortens the repolarization intervals of the atria and ventricles

  46. Therapeutic • Decreases depolarization & conduction through the SA and AV nodes. • These changes are reflected on ECG by: • decrease in ventricular response rate • PR interval prolongation • QT interval shortening • ST segment & T-wave opposite major QRS forces • scooped ST segment • Both these effects result in the characteristic “digitalis effect”

  47. Therapeutic • Some characteristic signs of digoxin therapy and toxicity. Digitalis effect Atrial flutter with PVC

  48. Clinical Toxicity

  49. Toxicologic • Effects mirror its therapeutic actions. • Bradydysrhythmias • (from increased VAGAL TONE) • Ventricular tachydysrhythmias • (from myocardial “irritability”) • Rapid atrial rhythms with slow ventricular response • (slowed AV conduction)

  50. 2 K+ 3 Na+ SR (Mitochondria) Phase 2 Ca2+ Ca2+ 3 Na+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Cell Electrophysiology

More Related